Drug Approval | December 28, 2024
Shilpa Medicare's Unit IV receives Eurasia GMP approval
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
The company has received the GMP Certification after successful closure of the inspection
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
This is used to treat central diabetes insipidus and bedwetting
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
The Unit has been issued GMP Certification from ANVISA-Brazil
Subscribe To Our Newsletter & Stay Updated
